Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study
Clinical Infectious Diseases · 17.03.2025 · 80 (3) · 540-550
DOI: 10.1093/cid/ciae603 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 15.01.2025. Verfasst von Antonio Vena und 21 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy. Hauptthemen laut MEDLINE: Fluconazole, Drug Resistance, Fungal, Antifungal Agents, Candida parapsilosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Plan Nacional de I+D+I 2017-2020.
Abstract (Originalsprache)
Background
This study assesses the impact of fluconazole resistance on 30-day all-cause mortality and 1-year recurrence in patients with Candida parapsilosis bloodstream infections (BSI).
Methods
A multicenter retrospective study was performed at 3 hospitals in Italy and Spain between 2018 and 2022. Adult patients with positive blood cultures for C. parapsilosis who received appropriate targeted therapy with either echinocandins or fluconazole were included.
Results
Among 457 patients, 196 (42.9%) had fluconazole-resistant C. parapsilosis (FLZR-CP) BSI and 261 (57.1%) had fluconazole-susceptible C. parapsilosis (FLZS-CP) BSI. All FLZR-CP patients received targeted echinocandins, while FLZS-CP patients received either echinocandins (60.5%) or fluconazole (39.5%). Unadjusted 30-day all-cause mortality rates were 28.6% for FLZR-CP and 28.4% for FLZS-CP (log-rank test, P = .998). In multivariable analysis, increased mortality was associated with age (adjusted hazard ratio [aHR] 1.03 per year; 95% confidence interval [CI], 1.01–1.05; P = .0005), solid tumor (aHR 1.91; 95% CI, 1.06–3.46; P = .0302), previous antifungal treatment (aHR 1.84; 95% CI, 1.12–3.10; P = .0192), and septic shock (aHR 2.39; 95% CI, 1.42–4.06; P = .0010), but not fluconazole resistance (aHR 1.00; 95% CI, .62–1.63; P = .9864) nor the type of initial antifungal therapy (aHR 1.46; 95% CI, .69–3.06; P = .3202). Propensity score-matched analysis showed no 30-day all-cause mortality difference between echinocandin-treated FLZR-CP and fluconazole-treated FLZS-CP patients (HR 0.81; 95% CI, .37–1.75; P = .5915). However, a higher 1-year recurrence risk was observed in FLZR-CP patients (odds ratio, 7.37; 95% CI, 2.11–25.80; P = .0018).
Conclusions
Our results suggest that fluconazole resistance is not associated with a higher mortality risk in patients with C. parapsilosis BSI, though 1-year recurrence rates were higher in the FLZR-CP group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy.
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
- Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
- Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
- Microbiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
ORCID-Profile: Giusy Tiseo, Marco Falcone, Cristina Marelli, Vincenzo Di Pilato, Pilar Escribano, Daniele Roberto Giacobbe, Alessandro Limongelli, Marina Machado, Malgorzata Mikulska, Lucia Taramasso, Maricela Valerio, Patricia Muñoz
Förderung
- Fondo de Investigación Sanitaria
- Instituto de Salud Carlos III
- Plan Nacional de I+D+I 2017-2020
- Bando Curiosity Driven 2021 Decreto Rettorale 5074 del 29/10/2021-Università di Genova
- European Regional Development Fund
Zitieren
APA
Vena, A., Tiseo, G., Falcone, M., Bartalucci, C., Marelli, C., Cesaretti, M., Di Pilato, V., Escribano, P., Forniti, A., Giacobbe, D. R., Guinea, J., Limongelli, A., Lupetti, A., Machado, M., Mikulska, M., Salmanton-García, J., Soriano-Martin, A., Taramasso, L., Valerio, M., …, & Bassetti, M. (2025). Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study. Clinical Infectious Diseases, 80(3), 540-550. https://doi.org/10.1093/cid/ciae603
Vancouver
Vena A, Tiseo G, Falcone M, Bartalucci C, Marelli C, Cesaretti M, et al. Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study. Clinical Infectious Diseases. 2025;80(3):540-550. doi:10.1093/cid/ciae603
BibTeX
@article{Vena2025,
author = {Vena, Antonio and Tiseo, Giusy and Falcone, Marco and Bartalucci, Claudia and Marelli, Cristina and Cesaretti, Mario and Di Pilato, Vincenzo and Escribano, Pilar and Forniti, Arianna and Giacobbe, Daniele Roberto and Guinea, Jesus and Limongelli, Alessandro and Lupetti, Antonella and Machado, Marina and Mikulska, Malgorzata and Salmanton-García, Jon and Soriano-Martin, Ana and Taramasso, Lucia and Valerio, Maricela and Bouza, Emilio and Muñoz, Patricia and Bassetti, Matteo},
title = {Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {3},
pages = {540--550},
doi = {10.1093/cid/ciae603}
}
EUVIMED